Impact of HCV Eradication on Neurocognitive Functions and CNS Metabolism: a Trial of Daclatasvir, Asunaprevir and BMS-791325 for Patients With HCV Genotype 1 Infection

Trial Profile

Impact of HCV Eradication on Neurocognitive Functions and CNS Metabolism: a Trial of Daclatasvir, Asunaprevir and BMS-791325 for Patients With HCV Genotype 1 Infection

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Asunaprevir/becabluvir/daclatasvir (Primary)
  • Indications Hepatitis C
  • Focus Pharmacokinetics; Therapeutic Use
  • Acronyms HEPCOG-II
  • Most Recent Events

    • 02 Jun 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 29 Apr 2015 Planned End Date changed from 1 Feb 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov.
    • 29 Apr 2015 Planned primary completion date changed from 1 Feb 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top